Biotech Values

[RockRat]

Yeah, that's the only thing I can come up with. Given how much is under seal, I wonder what Sanofi knows as an expert in the field. How good a tell is this action of theirs on the outcome of the PI or, later of validity at trial? Brings to mind Peter's point that MNTA has not sued Sanofi for infringement. I privately poo-pooed the point at the time (on the theory that the FDA requires a higher standard of QC proof from the generics, requiring MNTA's IP), but it seems relevant given the timing here.

Regards, RockRat